Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : CNTX save search
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 8.7%
H: 3.33%
C: -8.67%
ctim-76 application therapeutics
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 0.87%
H: 6.78%
C: -7.76%
year therapeutics financial results
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 0.43%
H: 0.01%
C: -2.44%
therapeutics financial results
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
Published: 2023-10-31 (Crawled : 13:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 0.97%
H: 6.73%
C: 1.92%
ctim-76 active antibody preclinical therapeutics
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Published: 2023-09-27 (Crawled : 13:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 0.0%
H: 25.2%
C: 16.22%
immunotherapy meeting therapeutics
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Published: 2023-08-09 (Crawled : 20:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 0.0%
H: 10.88%
C: 10.64%
therapeutics financial results
Context Therapeutics to Participate in Two August 2023 Investor Conferences
Published: 2023-08-01 (Crawled : 12:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 1.82%
H: 8.92%
C: 5.36%
therapeutics
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
Published: 2023-05-10 (Crawled : 20:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: -3.23%
H: 3.28%
C: -3.25%
therapeutics financial results
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
Published: 2023-03-22 (Crawled : 22:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: -9.09%
H: 2.33%
C: 1.65%
year pipeline therapeutics financial results
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Published: 2023-03-15 (Crawled : 12:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 4.4%
H: 4.93%
C: -2.61%
research meeting association therapeutics cancer
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
Published: 2023-02-06 (Crawled : 13:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: -0.15%
H: 13.11%
C: 5.44%
treatment ona-xr trial therapeutics cancer phase 2
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 78.62%
H: 27.05%
C: -13.11%
fda breast approval cancer group elascestrant orserdu ona-xr her2- her2
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Published: 2023-01-09 (Crawled : 14:00) - biospace.com/
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 51.28%
H: 9.32%
C: -28.4%
cancer antibody therapeutics agreement cldn6
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Published: 2022-12-08 (Crawled : 13:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: -28.77%
H: 13.02%
C: 0.49%
therapeutics breast cancer ona-xr phase 2 metastatic breast cancer
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
Published: 2022-11-29 (Crawled : 13:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 3.57%
H: 2.75%
C: -2.26%
ctim-76 therapeutics treatment candidate antibody tumors
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
Published: 2022-11-21 (Crawled : 14:20) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 1.61%
H: 5.56%
C: 0.79%
therapeutics breast symposium cancer ona-xr
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
Published: 2022-09-27 (Crawled : 12:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: -0.83%
H: 5.03%
C: -1.68%
therapeutics
Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting
Published: 2022-05-05 (Crawled : 12:20) - biospace.com/
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 1.39%
H: 6.85%
C: 2.05%
therapeutics presentation asco
Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
Published: 2022-04-11 (Crawled : 16:00) - biospace.com/
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: -2.6%
H: 0.65%
C: -20.17%
therapeutics research preclinical cancer pre-clinical
Context Therapeutics® to Participate in Two April 2022 Investor Conferences
Published: 2022-04-06 (Crawled : 12:00) - globenewswire.com
CNTX | $1.38 -2.13% -2.17% 37K
|
Health Technology
|
| O: 0.0%
H: 3.86%
C: 0.77%
therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.